HIF1A and neoplasm: Because CXCL12 is the target molecule of HIF-1α, the hypoxic condition resulting from bevacizumab treatment could lead the tumour cells to produce CXCL12, which would in turn prompt the CXCR4+ cells to migrate into the tumour.